Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. It has commercialized cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. Its commercial offering consists of a point of care technology for the separation of autologous blood to produce a platelet-based therapy for use in the chronic wound care market. The Aurix System produces a platelet-rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. The Aurix PRP comprises a natural, endogenous complement of protein and non-protein signal molecules that are believed to contribute to effective healing.